

DRUG DISCOVERY TODAY**Editorial**

Editor: Steve Carney
Content Development Manager: Pien van Spijker
Journal Manager: Bharathi Sims
Publisher: Fernanda Ogochi
Editorial Enquiries:
Drug Discovery Today
 Elsevier
 125 London Wall, London, EC2Y 5AS, UK
 Tel: +44 (0) 20 8439 5525
 Fax: +44 (0)1865 853067
 Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD

Jürgen Bajorath *University of Bonn, Germany*
Walter Blackstock *Experimental Therapeutics Centre, Singapore*
David Brayden *University College Dublin, Ireland*
Paul Caron *Integrated Profiling, USA*
David Cavalla *Numedica Ltd., UK*
David Clark *Argenta Discovery, UK*
Dalia Cohen *ALN Associates, USA*
Donald Daley *Argenta Discovery, UK*
Sean Ekins *Collaborations in Chemistry, USA*
Hans-Peter Fischer *GeneData, Switzerland*
Peter Ghazal *University of Edinburgh, UK*
Christopher M. Hill *Merck, USA*
Nick Hird *Takeda Chemical Industries, Japan*
Enoch Huang *Pfizer, USA*
Thomas Joos *University of Tuebingen, Germany*
Vincent H.L. Lee *Chinese University of Hong Kong, China*
David Lewin *Yale University, USA*
Christopher A. Lipinski *Meliior Discovery, USA*
Lorenz Mayr *AstraZeneca, UK*
Nick Meanwell *Bristol-Myers Squibb, USA*
BK Muralidhara *Accelaron Pharma Inc, USA*
Mark Murcko *Disruptive Biomedical, LLC, USA*
Fajun Nan *Shanghai Institute of Materia Medica, China*
Pradeep Nathan *Experimental Medicine, GSK and University of Cambridge*
Gitte Neubauer *Cellzome, Germany*
Eric Neumann *Clinical Semantics Group Consulting, USA*
Tim Peakman *UK Biobank, UK*
Norton Peet *Microbiotix, Inc., USA*
Manuel Peitsch *Swiss Institute of Bioinformatics, Switzerland*
Kurt Rasmussen *Eli Lilly and Co. Ltd., USA*
Janice Reichert *Reichert Biotechnology Consulting LLC, MA, USA*
John Reidhaar-Olson *Albert Einstein College of Medicine, New York, USA*
Mike Romanos *Crescendo Biologics, Cambridge, UK*
Raymond C. Rowe *Intelligensys, UK*
Andreas Russ *University of Oxford, UK*
Esther Schmid *EFS Strategy and Business Consulting, UK*
Jonathan Sheldon *Translational Medicine, Oracle, UK*
Michael Snyder *Stanford University, USA*
Susie Stephens *Johnson & Johnson, USA*
Robert Strausberg *Ludwig Institute for Cancer Research, New York, USA*
Yuichi Sugiyama *University of Tokyo, Japan*
David Szymkowski *Xencor, USA*
Nick Terrett *Ensemble Discovery, USA*
Vladimir Torchilin *Northeastern University, Boston, USA*
Mark Whittaker *Evotec OAI, UK*
Hans Winkler *Janssen Pharmaceutica, Belgium*
Limsoon Wong *National University of Singapore*
X.F. Steven Zheng *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

REVIEWS (continued)

1845 Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?

Elaine D. Gonçalves and Rafael C. Dutra

INFORMATICS

1854 Molecular modeling approaches for the discovery of adenosine A_{2B} receptor antagonists: current status and future perspectives

Pran Kishore Deb, Balakumar Chandrasekaran, Raghuprasad Mailavaram, Rakesh Kumar Tekade and Abdul Muttaleb Yousef Jaber

POST SCREEN

1865 Physicians in the pharmaceutical industry: their roles, motivations, and perspectives

Hussein Sweiti, Frank Wiegand, Christoph Bug, Martin Vogel, Frederic Lavie, Ivo Winiger-Candolfi and Maximilian Schuier

1871 Correlates of time to approval and other clinical development periods

Christopher D. Breder, Margaret VanHeusen and Lin-Chau Chang

1877 Peptide-based protease inhibitors from plants

Roland Hellinger and Christian W. Gruber

1890 Advances and challenges in developing andrographolide and its analogues as cancer therapeutic agents

Hon Liong Soo, Shun Ying Quah, Ibrahim Sulaiman, Sreenivasa Rao Sagineedu, Jonathan Chee Woei Lim and Johnson Stanslas

1899 Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review

Siamaque Kazem, Emma Charlotte Linssen and Susan Gibbs

1911 Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges

Carla Vitorino, SoraiaSilva, JoanaBicker, AmílcarFalcão and Ana Fortuna

1924 Future unmet medical need as a guiding principle for pharmaceutical R&D

Matthias Vennemann, Vincent Ruland, Jan-Philip Kruse, Christine Harloff, Hubert Trübel and Heike Gielen-Haertwig

1930 Toward a repositioning of the antibacterial drug nifuroxazide for cancer treatment

Christian Bailly

1937 Endothelin-1 traps as a potential therapeutic tool: from diabetes to beyond?

Arjun Jain, Charles Coffey, Vidhi Mehrotra and Josef Flammer

1943 Using molecular-mimicry-inducing pathways of pathogens as novel drug targets

Anjali Garg, Bandana Kumari, Neelja Singhal and Manish Kumar

CORRIGENDUM

1953 Corrigendum to 'Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development' *Drug Discovery Today* 23 (2018) 1733–1745

Shalini Andersson, Madeleine Antonsson, Marie Elebring, Rasmus Jansson-Löfmark and Lars Weidolf

FORTHCOMING ARTICLES:

Are we ready to close the discussion on the interchangeability of biosimilars?

By Hans C. Ebbers & Huub Schellekens.

Deep learning in drug discovery: opportunities, challenges, and future prospects.

By Antonio Lavecchia.

Exosomal miRNA in Chemoresistance, Immune Evasion, Metastasis and Progression 2 of Cancer.

By Bhagyashri Kulkarni, Prathibha Kirave, Piyush Gondaliya, Kavya Jash, Alok Jain, Rakesh K. Tekade and Kiran Kalia.

Revisiting mTOR inhibitors as anti-cancer agents.

By Qiu-Xu Teng, Yunali V. Ashar, Pranav Gupta, Eddie Gadee, Ying-Fang Fan, Sandra E. Reznik, John N.D. Worpel and Zhe-Sheng Chen.v